VRTX · 10-Q · 2026Q3 · Full report

ALYFTREK Royalty Arbitration

VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 40 · Surprise 42

On October 10, 2025, Royalty Pharma and the Cystic Fibrosis Foundation initiated confidential arbitration over royalties on ALYFTREK sales. Vertex maintains that the royalty burden is 4%, while the claimants allege it is approximately 8% and seek a declaratory judgment, alleged unpaid royalties and other damages, costs, attorneys’ fees, and interest. The dispute concerns the royalty terms under the CFF Agreement; Vertex states that it intends to defend its position.

Key facts

• Royalty Pharma and the Cystic Fibrosis Foundation initiated confidential arbitration on October 10, 2025, alleging ALYFTREK royalties are approximately 8% and seeking a declaration, alleged unpaid royalties and damages, costs, expenses, attorneys’ fees and interest. source
• The royalty burden on TRIKAFTA/KAFTRIO is 9.33%, while Vertex’s position is that ALYFTREK’s royalty burden is 4%. source
• Vertex intends to vigorously defend its position in the ALYFTREK royalty arbitration, stating that Royalty Pharma’s position is contrary to the plain terms of the CFF Agreement. source